REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Conditions: Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Platinum-resistant Ovarian Cancer Interventions: Drug: Luveltamab tazevibulin; Drug: Pegfilgrastim Sponsor: Sutro Biopharma, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Fallopian Tube Cancer | Ovarian Cancer | Ovaries | Peritoneal Cancer | Research | Study | Women